INTRODUCTION
Familial combined hyperlipidemia (FCHL) is the most frequent, dominantly inherited disorder of lipid metabolism leading to increased risk for atherosclerosis (1) (2) (3) (4) (5) (6) (7) (8) . The diagnosis is based on clinical criteria such as the presence of "multiple type hyperlipidemia", increased plasma apoB, and a positive family history of premature coronary heart disease (CHD) (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) . Abdominal obesity and increased BMI have been identified as independent factors for the development of hyperlipidemia and CHD in FCHL (4, 8, (10) (11) (12) . Associations with the complement system have also been reported (13, 14) . The genetic basis of FCHL has not been elucidated, although several groups have provided evidence suggesting that different genes are involved in the pathogenesis of this disorder (15) (16) (17) (18) (19) (20) (21) (22) (23) .
Impaired FFA metabolism, in the postprandial as well as in the post-absorptive period, is closely related to the expression of the FCHL phenotype (24) (25) (26) (27) (28) . FCHL patients have increased postprandial FFA concentrations compared to healthy controls (24, 26, 27) . In vitro and in vivo experiments have demonstrated that the uptake of FFA by peripheral cells is stimulated by acylation stimulating protein (ASP) (29,30), which is one of the immunologically inactive cleavage products of C3 (30). Different studies, in FCHL and non-FCHL subjects have shown a strong correlation between fasting C3 concentrations and fasting lipid-parameters, especially plasma triglycerides (TG) (13, 14, 27, 31, 32) . Furthermore, C3 is a powerful indicator of the risk of myocardial infarction in men (32) , and recently, it has been shown that C3 depositions are found predominantly in ruptured atherosclerotic plaques in humans (33) , suggesting a pathogenetic involvement in the process of atherosclerosis and acute coronary syndromes. Moreover, both fasting and postprandial C3 concentrations can be decreased by treatment with statins and this has been associated with an improvement in postprandial triglyceridemia (31).
The present study was carried out to evaluate the effects of atorvastatin in FCHL on postprandial lipemia and C3 changes. In addition, postprandial FFA changes and hydroxybutyric acid (HBA), reflecting hepatic FFA delivery, were also evaluated.
MATERIALS AND METHODS

Subjects
The study protocol was approved by the Human Investigations Review Committee of the University Medical Center Utrecht. All participants gave written informed consent. Twelve unrelated FCHL patients were recruited from the Lipid Clinic of the University Medical Center Utrecht. All untreated FCHL subjects met the criteria described previously (24, 26, 27) and used by different groups (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) Cream was used as fat source. To the cream 60 g/L dextrose and vitamin A were added (26).
After an overnight fast of 12 hours, the subjects ingested the fresh cream, in a dose of 50 g fat/m 2 body surface and 7.5 g dextrose/m 2 body surface. After ingestion of the fat load, the participants were allowed to drink only water and sugar-free tea during the following 24
hours. Peripheral blood samples were obtained in sodium EDTA (2 mg/mL) before (t=0 hr) and at hourly intervals up to 10 hours after the fat load and after 12 and 24 hours. For measurement of hydroxybutyric acid (HBA) every 2 hours blood samples were obtained in heparin tubes. Blood was placed on ice and centrifuged immediately for 15 min at 800 g at 4°C. Plasma samples were stored at -20°C immediately after centrifugation.
Study protocol
All patients stopped lipid-lowering drugs 4 weeks before the oral fat load but they continued their usual diet. Glucose was measured by glucose oxidase by dry chemistry (Vitros GLU slides) and colorimetry, and insulin was measured by commercial ELISA (Mercodia, Uppsala, Sweden).
ApoB48 and apoB100 concentrations in chylomicron fractions (Sf>400) were determined according to the method used by Karpe et al. (34) , and described in detail previously (35) .
Post-heparin plasma LPL and HL activities were determined by the release of free fatty acids from [ 14 C]-labeled trioleoyl emulsion. ASP was measured using the ELISA kindly provided by Dr. K Cianflone, as described previously (27). For estimation of insulin sensitivity, the homeostasis model assessment (HOMA =glucose*insulin/22.5) was calculated.
Statistics
All values are expressed as mean ± standard error of the mean (SEM Calculations were performed using SPSS/PC 10.0 (SPSS Inc. Chicago, IL, USA).
Calculations of AUC's were performed with GraphPad Prism version 3.0 (GraphPad Software Inc. San Diego, CA, USA). Statistical significance was reached when P<0.05 (twotailed).
RESULTS
General characteristics of untreated FCHL patients and controls (Tables 1 & 2)
FCHL patients and controls did not differ in anthropometric characteristics (Table 1) . Fasting plasma TG, cholesterol, apoB, C3 and insulin were significantly higher in untreated FCHL compared to controls. Fasting ASP concentrations were not different in untreated FCHL compared to controls. FCHL patients were more insulin resistant than controls, according to the elevated HOMA index (Table 2) .
Treatment effects of atorvastatin (Table 2)
After 16 weeks, 2 patients were using atorvastatin at a dose of 10 mg, 4 patients 20 mg, 1 patient 40 mg and 5 patients 80 mg atorvastatin. Except for age (36±4 and 52±2 years, respectively; P=0.01) the anthropometric characteristics were not different between the group using the lower doses upto 40 mg and the five subjects on 80 mg. There were no significant differences in baseline (off-treatment) characteristics in the seven subjects at low doses compared to the five at high doses.
After the final dose-adjustment, the patients at 80 mg had significantly higher fasting plasma In the total FCHL group, atorvastatin significantly lowered plasma TG, cholesterol, apoB and C3 concentrations (Table 2) . Plasma apoB concentrations reached normal levels as compared to controls and plasma cholesterol concentrations were reduced below the mean levels in these control subjects. These effects were minly due to a reduction of LDL-apoB (data not shown). LPL and HL concentrations were not different in FCHL patients and controls and were not effected by atorvastatin. HDL-C, apoAI, ASP and anthropometric characteristics did not change after treatment.
Postprandial C3 changes (Table 2 and Figure 1)
Fasting plasma C3 concentrations decreased after atorvastatin, but were still elevated compared to controls (Table 2) . Before treatment, the first significant increase in C3 concentration was seen 6 hours after fat intake in FCHL (upto 1.49±0.16 g/L). In controls, however, C3 increased significantly already after two hours (upto 1.02±0.04 g/L). After treatment, no significant increase was seen over time by repeated measures ANOVA, but there was a tendency to increase 4 hours after fat intake (1.27±0.06 g/L; P=0.09). (Figure 1 , right panel), with a maximal relative postprandial increase of 9.8±8.6% before and 6.2±3.0% after atorvastatin compared to a 21.8±3.8% increase in controls. C3-AUC was still higher after treatment than in controls.
When the group using upto 40 mg atorvastatin was compared to the group using 80 mg, fasting C3 (1.27±0.07 and 1.21±0.08 g/L, respectively) and postprandial C3-AUC (9.49±0.50 and 9.36±0.49 g/L, respectively) were not different.
Plasma TG, FFA and hydroxybutyric acid changes (Figures 2A, B and C)
In A significant increase of apoB100, from fasting to a peak at 6 hours postprandially was found 
Determinants of fasting and postprandial C3 levels (Table 3)
All significant correlations between fasting C3 and postprandial C3, represented as C3-AUC, apoB, postprandial plasma TG, FFA, apoB48, apoB100 and (Sf>400)-TG and general characteristics are listed in Table 3 . Multiple regression analysis showed that the best determinant of fasting C3 in all subjects was the fasting plasma TG (adjusted R (36) . This is supported by in vivo stable isotope studies in patients with combined hyperlipidemia (37) . Atorvastatin improves the clearance of chylomicron remnants, but it does not have an effect on the production of intestinal lipoproteins, e.g. chylomicrons (38) (39) (40) . In our FCHL patients, atorvastatin lowered fasting plasma TG, cholesterol and apoB. Neither HDL-cholesterol nor apoAI improved after treatment.
Fasting C3 levels were correlated with the different lipid parameters, like fasting plasma TG, cholesterol, and apoB concentrations and also to insulin and HOMA, as a marker for insulin resistance, in accordance with different previous studies (13, 14, 27, 31, 32) . C3 is the precursor of ASP and plays an important role in FFA uptake by adipocytes, following lipolysis of chylomicrons (29). In a previous study we found that untreated FCHL had higher fasting C3
and an exaggerated and delayed postprandial C3 response (27). We concluded that this could be a consequence of C3-resistance at the level of adipocytes. The latter could result in It has been suggested that chylomicrons compete efficiently with VLDL for the same lipolytic pathway (46) , which leads to accumulation of postprandial VLDL (47) . In the present study we found a significant reduction of postprandial plasma triglycerides without improvement of large TRL-apoB48 or apoB100 clearance. This may have been due to the relatively small sample size of FCHL patients and to the fact that fasting plasma TG (the best determinants of postprandial lipemia) were not normalized. However, in other postprandial studies investigating the effects of atorvastatin, including similar numbers of non-FCHL participants, statistical significant improvements have been reported (39, 40) . This underlines once again how difficult it is to reduce postprandial lipemia in FCHL subjects (48, 49) . The small nonsignificant changes obtained by atorvastatin of postprandial apoB100 and apoB48 clearance suggest that a more effective reduction of fasting plasma TG could improve postprandial lipemia in this disorder.
It should be noted that total plasma apoB was normalized in FCHL by atorvastatin, in contrast to the less efficient reduction of fasting plasma TG. This may be explained by the fact that atorvastatin reduced dramatically LDL with less significant effects on large TRL's. In a recent paper by Parhofer and co-workers, atorvastatin significantly reduced the postprandial concentrations of large TRL's with less effect on small TRL's in 10 hypertriglyceridemic patients (50) . Detailed data on the effects of atorvastatin on lipoprotein composition in FCHL will be published separately.
All patients were treated with their own minimal dose of atorvastatin to reach a normolipidemic state, resembling the situation in clinical practice where titration to optimal doses is prescribed to patients. However, 5 of the 12 patients were treated with the maximal dose, 80 mg, and had still increased fasting and postprandial plasma TG levels. Although they Table 3 Spearman's correlation coefficients between fasting and postprandial C3-AUC and biochemical variables in untreated FCHL patients and controls. Only significant correlations are given. * P<0.05 and † P<0.01. 
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